Proteomic Differences in 3D vs 2D Ovarian Cancer Models and Carboplatin Response

Study Background and Research Question

High-grade serous ovarian carcinoma (HGSOC) is the most prevalent and lethal subtype of ovarian cancer, contributing to over 200,000 deaths annually worldwide. Despite advances, prognosis remains poor due to late-stage diagnosis and the frequent emergence of resistance to platinum-based DNA synthesis inhibitors such as carboplatin. Most preclinical drug discovery relies on two-dimensional (2D) monolayer cell cultures, which fail to fully recapitulate the complex tumor microenvironment, including cell–cell and cell–matrix interactions. Three-dimensional (3D) spheroid models offer a more physiologically relevant context, but a comprehensive proteomic comparison between 2D and 3D HGSOC cultures had been missing. This gap limits our understanding of how culture dimensionality may drive drug resistance and affect the interpretation of preclinical oncology research.

Key Innovation from the Reference Study

The reference study (J. Proteome Res. 2025, 24, 5071−5082) delivers the first quantitative, whole-proteome comparison of four HGSOC cell lines—PEO1, PEO4, UWB1.289, and UWB1.289+BRCA1—cultured in both 2D and 3D conditions. Using isobaric labeling and mass spectrometry, the authors identified 6,404 proteins and detailed 371 commonly altered proteins between the two culture formats. Critically, the study connects these proteomic shifts to altered carboplatin response, highlighting mechanisms of drug resistance that are only observable in 3D models. This innovation helps bridge the translational gap between in vitro studies and clinical outcomes in ovarian cancer therapy.

Methods and Experimental Design Insights

The investigators selected cell lines representing both platinum-sensitive (PEO1, UWB1.289) and resistant (PEO4, UWB1.289+BRCA1-restored) states, including isogenic pairs to control for genetic background. Both 2D monolayer and 3D spheroid cultures were established, and whole-cell lysates were subjected to isobaric labeling quantitative proteomics. The workflow enabled the quantification of thousands of proteins in parallel, providing a robust basis for comparative analysis. Statistical methods were applied to identify proteins significantly and consistently altered by dimensionality across all cell lines. Pathway enrichment analysis further contextualized these proteomic changes by their biological functions.

Protocol Parameters

• Cell line selection: Use genetically related HGSOC lines (e.g., PEO1/PEO4, UWB1.289/UWB1.289+BRCA1), as these permit direct assessment of platinum resistance and BRCA status effects.
• 3D spheroid formation: Initiate spheroid culture using ultra-low attachment plates; allow 5–7 days for spheroid maturation before proteomic analysis, as per the reference workflow.
• Proteomic profiling: Employ isobaric labeling (e.g., TMT or iTRAQ) with high-resolution LC-MS/MS to achieve deep proteome coverage.
• Drug challenge: Apply carboplatin at IC50 concentrations established for each cell line; compare responses after equivalent duration in 2D and 3D cultures.

Core Findings and Why They Matter

The study revealed that 3D spheroids display a proteomic landscape distinct from 2D monolayers. Notably, 3D-cultured cells upregulated proteins related to transmembrane transport and mitochondrial complex I (NADH:ubiquinone oxidoreductase), while downregulating membrane-associated proteins—including EGFR, particularly in the PEO1 line. Pathways involved in energy metabolism and cell growth exhibited dimensionality-dependent regulation. Most significantly, 3D culture increased baseline expression of drug resistance-associated proteins, such as NDUF family members, across all spheroid models. This molecular adaptation coincided with reduced sensitivity to carboplatin, underscoring the importance of 3D models for evaluating chemotherapeutic efficacy and resistance mechanisms (reference study).

These findings challenge the translational relevance of standard 2D cultures for predicting clinical responses to platinum-based DNA synthesis inhibitors. They also highlight candidate targets for overcoming carboplatin resistance, such as mitochondrial metabolism regulators and membrane-associated proteins, which are differentially regulated in 3D contexts. This has direct implications for preclinical oncology workflows, where accurate modeling of tumor microenvironment-driven resistance is essential.

Comparison with Existing Internal Articles

Insights from this study align with and expand upon prior thought-leadership content on platinum-based DNA synthesis inhibitors in oncology. For example, "Strategic Innovation in Preclinical Oncology" emphasizes the necessity of mechanistically informed, physiologically relevant cancer models for investigating metabolic reprogramming and drug resistance. The current proteomic study provides direct molecular evidence supporting this approach, identifying specific energy metabolism pathways and membrane proteins altered by 3D growth that may underlie resistance to carboplatin.

Similarly, the review "Topotecan vs. Carboplatin Regimens in Ovarian Cancer" highlights the ongoing need to optimize platinum-based regimens in the context of chemoresistance. The proteomic changes observed here offer concrete candidates for stratification and rational combination strategies. Furthermore, the workflow-focused article "Carboplatin (SKU A2171): Reliable Platinum-Based DNA Synt..." provides guidance for deploying carboplatin in cell-based assays, which can be adapted to spheroid protocols as outlined in the reference study.

Limitations and Transferability

While this study delivers a high-resolution map of proteomic alterations in 3D versus 2D HGSOC models, several limitations merit consideration. Proteomic changes may be cell line-specific, and while four lines with distinct BRCA backgrounds were included, broader generalizability remains to be tested. The in vitro 3D spheroid system, though more representative of in vivo tumors than monolayers, still lacks the full complexity of the tumor microenvironment, including immune and stromal components. Carboplatin response was evaluated in vitro, and translation to in vivo or clinical settings requires further validation. Finally, the study's focus on protein abundance does not address post-translational modifications or spatial proteomics, which may also modulate drug response.

Research Support Resources

For researchers designing preclinical oncology studies, these findings underscore the value of integrating 3D spheroid cultures and quantitative proteomics to model carboplatin resistance mechanisms. To replicate or extend such workflows, Carboplatin (SKU A2171) from APExBIO offers a well-characterized platinum-based DNA synthesis inhibitor suitable for both 2D and 3D cell proliferation and cytotoxicity assays. The product’s detailed solubility and storage guidance support reproducible experimentation across a range of ovarian and lung cancer cell line models. For further workflow insights and protocol optimization, see "Carboplatin in Preclinical Oncology: Quantitative Precision and Translational Impact" for guidance on assay selection and data interpretation in advanced cancer research settings.